BioDelivery Sciences sales may jump on DEA move, says Summer Street Summer Street believes the Drug Enforcement Agency's announcement yesterday that it will reschedule all hydrocodone combination products to schedule II from schedule III could allow BioDelivery Sciences's BEMA Buprenorphine to potentially reach significantly higher sales levels. The firm says BEMA Buprenorphine will now have an easier compare against Vicodin and generic equivalents. Summer Street has a Buy rating on BioDelivery with a $20 price target.
Summer Street still feels Endo could acquire BioDelivery Sciences Summer Street reiterated its belief that Endo (ENDP) could acquire BioDelivery Sciences (BDSI), its partner on multiple products. The firm says scripts for BioDelivery's Bunavail continue to trend in the right direction. It reiterates a Buy rating on the stock with a $25 price target.